-+ 0.00%
-+ 0.00%
-+ 0.00%

Cantor Fitzgerald Assumes Vanda Pharmaceuticals at Overweight, Announces Price Target of $13

Benzinga·05/14/2025 14:04:26
Listen to the news
Cantor Fitzgerald analyst Olivia Brayer assumes Vanda Pharmaceuticals (NASDAQ:VNDA) with a Overweight rating and announces Price Target of $13.